Molecular diagnostics firm gains $34M in VC
Amsterdam-based Agendia, a molecular diagnostics company, has raised $34 million in its fourth venture round, adding ING to its list of backers. Current investors Van Herk Biotech, Gilde Healthcare Partners and Global Life Science Ventures also participated. The company developed the MammaPrint, a prognostic DNA microarray-based in vitro diagnostic test that measures the activity of 70 genes to assess the risk of breast cancer recurrence.
- check out the release on the latest round
Related Article:
Personalized medicine advances with Agendia's new genetic test. Report
Diagnostics tied to new drugs. Report
Be the first to comment
More stories about Venture Capital New Drugs molecular diagnostics genes Agendia personalized medicine MammaPrint
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
